Advertisement

Potential der ERCC1 und c-erbB-2 Genexpression zur Prädiktion des Responseverhaltens auf die neoadjuvante Radiochemotherapie beim Ösophaguscarcinom

  • Ralf Metzger
  • P. M. Schneider
  • U. Warnecke-Eberz
  • F. Miyazono
  • S. Baldus
  • H. Schäfer
  • A. H. Hölscher
Conference paper
Part of the Deutsche Gesellschaft für Chirurgie book series (DTGESCHIR, volume 31)

Abstract

Objective: ERCC1 encodes for a nucleotide excision repair (NER) gene involved in repair of radiation and chemotherapy induced DNA-damage, especially cis-platinum (CDDP) mediated interstrand crosslinks. The c-erbB-2 gene also known as HER2/neu is coding for a transmembrane glycoprotein (pl85) with tyrosine kinase activity being a member of the type 1 growth factor receptor family. We examined the potential of ERCC1 as well as c-erbB-2 mRNA expression to predict response and non-response in patients with locally advanced esophageal cancer treated with neoadjuvant radiochemotherapy. Methods: 30 patients with resectable, locally advanced esophageal cancer (cT3,Nx,M0) underwent neoadjuvant radiochemotherapy (CDDP, 5-FU, 36Gy). All tumors were resected by transthoracic en bloc esophagectomy and objective histomorphologic regression was defined: Grade I: minor response/no change (< 50% regression), II: partial response with 10 – 50% residual vital tumor cells, III: near complete response with < 10% residual vital tumor cells, and grade IV with histomorphologic complete remission (pCR, ypT0). Objective histomorphologic regression was defined as major response when < 10% residual vital tumor cells or pathologic complete response (pCR) was accomplished (Grade III, IV).

Tissue samples were collected by endoscopic biopsy prior to treatment. Quantitation of ERCC1 and c-erbB-2 mRNA expression was performed using quantitative real time RTPCR with specific primers using β-actin as internal control. Relative ERCC1 or c-erbB-2 expression was calculated as (ERCC1 or c-erbB-2/β-actin in tumor)/(ERCCl or c-erbB-2/β-actin in paired normal tissue). Results: Comparison of quantitative gene expression to histomorphologic regression showed that relative ERCC1 and/or c-erbB-2 expression levels > 1.12 were not associated with major response (grade III, IV) to radiochemotherapy. With this approach 12/30 patients were identified having no major response after neoadjuvant radiochemotherapy. Conclusion: Our study shows that quantitative ERCC1 and c-erbB-2 mRNA expression could serve as a predictor of response identifying those patients with esophageal cancer who will not benefit from neoadjuvant radiochemotherapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Hölscher AH, Metzger R, Schneider PM (2000) Präoperative Radiochemotherapie des Ösophaguscarcinoms. Zentralbl Chir 125: 319–325PubMedGoogle Scholar
  2. 2.
    Houtsmuller AB, Rademakers S, Nigg AL, Hoogstraten D, Hoeijmakers JH, Vermeulen W (1999). Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 284: 958–961PubMedCrossRefGoogle Scholar
  3. 3.
    Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309–316PubMedGoogle Scholar
  4. 4.
    Kumar R, Yarmand-Bagheri R (2001) The role of HER2 in angiogenesis. Semin Oncol 28: 27–32PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Ralf Metzger
    • 1
    • 4
  • P. M. Schneider
    • 1
  • U. Warnecke-Eberz
    • 1
  • F. Miyazono
    • 2
  • S. Baldus
    • 3
  • H. Schäfer
    • 1
  • A. H. Hölscher
    • 1
  1. 1.Klinik und Poliklinik für Visceral- und GefäßchirurgieUniversität KölnGermany
  2. 2.First Department of SurgeryKagoshima University School of MedicineKagoshimaJapan
  3. 3.Institut für PathologieUniversität KölnGermany
  4. 4.Klinik und Poliklinik fur Visceral- und GefäfkhirurgieUniversität zu KölnKölnGermany

Personalised recommendations